CHMP Recommends EU Approval for Ionis' TRYNGOLZA in Severe Hypertriglyceridemia

Key Facts

1The CHMP adopted a positive opinion recommending the approval of TRYNGOLZA (olezarsen) for the treatment of severe hypertriglyceridemia.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Ionis Pharmaceuticals' drug TRYNGOLZA (olezarsen). Business Wire reported that the recommendation serves as an adjunct treatment for adults with severe hypertriglyceridemia, supported by clinical data demonstrating the drug's efficacy in lowering fasting triglyceride levels.

IONS closed at $44.12 on October 15, 2026, after trading between a session low of $43.42 and a high of $44.71. This regulatory milestone from the European Medicines Agency typically precedes final European Commission approval, potentially opening the European market for this Ionis therapeutic.